Mitoxantrone Hydrochloride Liposome, Gemcitabine, Vinorelbine with or without Rituximab (GVM±R) in Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

被引：0
|
作者：
Liu, Wei [1 ]
Wang, Yi [1 ]
Xu, Yan [1 ]
Du, Chenxing [1 ]
Wang, Qi [1 ]
Wang, Tingyu [1 ]
Huang, Wenyang [1 ]
Zhang, Shuaishuai [1 ]
Yi, Shuhua [1 ]
Yan, Yuting [1 ]
Yu, Tengteng [1 ]
Sui, Weiwei [1 ]
An, Gang [1 ]
Lyu, Rui [1 ]
Liu, Huimin [1 ]
Xiong, Wenjie [1 ]
Fu, Mingwei [1 ]
Zou, Dehui [1 ]
Qiu, Lugui [1 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-185669
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Activity of vinorelbine/gemcitabine in relapsed/refractory Hodgkin's and non-Hodgkin's lymphoma
    不详
    CLINICAL LYMPHOMA, 2003, 3 (04): : 207 - 208
  • [2] Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma
    Belada, David
    Georgiev, Pencho
    Dakhil, Shaker
    Inhorn, Lowell F.
    Andorsky, David
    Beck, J. Thaddeus
    Quick, Donald
    Pettengell, Ruth
    Daly, Robert
    Dean, James P.
    Pavlyuk, Mariya
    Failloux, Nelly
    Huebel, Kai
    FUTURE ONCOLOGY, 2016, 12 (15) : 1759 - 1768
  • [3] Gemcitabine and vinorelbine chemotherapy for refractory or relapsing aggressive non-Hodgkin lymphoma
    Sivam, Vanessa
    Cook, Lucy
    Hughes, George
    Karadimitris, Anasatasios
    Marks, Alexandra J.
    Matthey, Francis
    Naresh, Kikkeri N.
    Szydlo, Richard M.
    Yarranton, Helen
    Kanfer, Edward J.
    Macdonald, Donald H.
    HEMATOLOGICAL ONCOLOGY, 2012, 30 (04) : 214 - 215
  • [4] Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma
    Fosså, A
    Santoro, A
    Hiddemann, W
    Truemper, L
    Niederle, N
    Buksmaui, S
    Bonadonna, G
    Seeber, S
    Nowrousian, MR
    JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (12) : 3786 - 3792
  • [5] Efficacy of Gemcitabine as Salvage Therapy for Relapsed and Refractory Aggressive Non-Hodgkin Lymphoma
    Zlotnick, Maya
    Avigdor, Abraham
    Ribakovsky, Elena
    Nagler, Arnon
    Kedmi, Meirav
    ACTA HAEMATOLOGICA, 2019, 141 (02) : 84 - 90
  • [6] Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma
    Ogura, Michinori
    Ando, Kiyoshi
    Taniwaki, Masafumi
    Watanabe, Takashi
    Uchida, Toshiki
    Ohmachi, Ken
    Matsumoto, Yosuke
    Tobinai, Kensei
    CANCER SCIENCE, 2011, 102 (09) : 1687 - 1692
  • [7] Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.
    Krämer, A
    Zoz, M
    Krasniqi, F
    Görner, M
    Leo, E
    Ho, AD
    BLOOD, 2001, 98 (11) : 135A - 135A
  • [8] Gemcitabine as single agent in the treatment of relapsed or refractory aggressive non-Hodgkin lymphoma (NHL)
    Welt, A
    Fossa, A
    Blatter, J
    Buksmaui, S
    Seeber, S
    Nowrousian, MR
    ANNALS OF ONCOLOGY, 1998, 9 : 168 - 168
  • [9] A phase II study of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed or refractory non-Hodgkin lymphoma
    Ikoma, Yoshikazu
    Nakamura, Nobuhiko
    Kitagawa, Junichi
    Miwa, Takao
    Takada, Eri
    Matsumoto, Takuro
    Shibata, Yuhei
    Nakamura, Hiroshi
    Kanemura, Nobuhiro
    Kasahara, Senji
    Hara, Takeshi
    Sawada, Michio
    Tsurumi, Hisashi
    Shimizu, Masahito
    HEMATOLOGICAL ONCOLOGY, 2024, 42 (01)
  • [10] Treatment strategies for relapsed and refractory aggressive non-Hodgkin's lymphoma
    Prichard, Mark
    Harris, Thomas
    Williams, Michael E.
    Densmore, John J.
    EXPERT OPINION ON PHARMACOTHERAPY, 2009, 10 (06) : 983 - 995
12345